A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers

A Long-term Follow-up Study to Assess the Persistence of Immunoglobin G (IgG) Antibodies to the GBS-NN/NN2 Vaccine After Vaccination With the GBS-NN/NN2 Vaccine in MVX0002 and/or in MVX0003

The goal of this follow-up study is to investigate the persistence of the immune response induced by the GBS-NN/NN2 vaccine in women who have participated in study MVX0002, and/or in study MVX0003 with GBS-NN/NN2 vaccine and received 1, 2 or 3 doses of GBS-NN/NN2. The main question it aims to answer is to determine the persistence of the immune response induced by the GBS-NN/NN2 vaccine by measuring antibody concentrations.

Participants who had received a primary course of GBS-NN/NN2 in Study MVX0002 and/or MVX0003 will be invited to return to have a single yearly blood sample of approximately 10 mL collected 2 to 5 years after the completion of the previous vaccination.

Study Overview

• Status: Terminated
• Conditions: Group B Streptococcus Infection
• Intervention / Treatment: Biological: GBS-NN/NN2

Detailed Description

This is a follow-up study to investigate the persistence of the immune response induced by the GBS-NN/NN2 vaccine. No vaccine or placebo will be administered. A single 10 mL blood sample will be collected from participants, every year, for a maximum of 4 years. Participants who had received a primary course of GBS-NN/NN2 in Study MVX0002 and/or MVX0003 will be invited to return to have a single yearly blood sample of approximately 10 mL collected 2 to 5 years after the completion of the previous vaccination.

Only participants that received two doses GBS-NN/NN2 in MVX0002 and all participants that received a single dose in MVX0003 will be eligible.

Hence, participants will have received:

One dose of GBS-NN/NN2 prior to this study, i.e., participants from MVX0003 who had not received GBS-NN/NN2 in MVX0002 and received a single dose in MVX0003.

Or two doses of GBS-NN/NN2 prior to this study, i.e., participants from MVX0002 who had received two doses of GBS-NN/NN2 in MVX0002 and did not take part in MVX0003.

Or three doses of GBS-NN/NN2 prior to this study, i.e., participants from MVX0003 who had received two doses of GBS-NN/NN2 in MVX0002 and received a single dose in MVX0003.

• Study Type: Observational
• Enrollment (Actual): 29

Contacts and Locations

Study Locations

• United Kingdom
  • Pentrebach Merthyr Tydfil CF48 4DR
    • Merthyr Tydfil, Pentrebach Merthyr Tydfil CF48 4DR, United Kingdom
      • Simbec-Orion Clinical Pharmacology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

A minimum of 20 and a maximum of 55 female participants, all of whom received previous vaccination with GBS-NN/NN2 in the MVX0002 and MVX0003 studies, will be recruited.

Description

Inclusion Criteria:

1. Women who have participated in study MVX0002, and/or in study MVX0003 with GBS-NN/NN2 vaccine and received 1, 2 or 3 doses of GBS-NN/NN2.
2. Able to voluntarily provide written informed consent to participate in the study.
3. Participant must be fit to participate in the study, as assessed by the investigator.
4. Participant must be able to comply with study procedures and provide at least 2 blood samples.

Exclusion Criteria:

1. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or MinervaX employees, including their family members.
2. Any known or suspected immunocompromising or immune suppressive condition (including conditions caused by certain immunocompromising/immunosuppressive medication), unless the condition is expected to normalise within 12 weeks after enrolment. If this is the case, then the subject can be enrolled but the blood sampling will be postponed until the condition has normalised.
3. Received systemic steroids in the 6 weeks before any blood sampling (inhaled and topical steroids are acceptable).
4. Received blood, blood products, plasma derivatives or any immunoglobulin preparations in the 12 weeks before any blood sampling.
5. While participants who are enrolled on this study will also be eligible for participation in other clinical trials which may be ongoing during the overall period of participation in this study, they are not allowed to participate in another vaccine study nor in a study involving a licensed or investigational drug which is known or suspected to have an impact on the immune response (immune compromising/suppressing/stimulating).

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
One dose of GBS-NN/NN2; Participants who participated in study MVX003 and had received one dose of GBS-NN/NN2 prior to this study.	Biological: GBS-NN/NN2; GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
Two doses of GBS-NN/NN2; Participants who participated in study MVX002 and had received two doses of GBS-NN/NN2 prior to this study.	Biological: GBS-NN/NN2; GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
Three doses of GBS-NN/NN2; Participants who participated in study MVX002 and MVX003 and had received three doses of GBS-NN/NN2 prior to this study.	Biological: GBS-NN/NN2; GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Antibody Concentration Specific for GBS-NN and GBS-NN2	Pharmacodynamic (PD) blood samples (10 mL) for antibody concentration specific for GBS-NN and GBS-NN2 will be collected during the study.	Baseline (Year 0), Years 1, 2, 3, 4
Ig G Antibody Responses Specific to Alpha like proteins (Alp): AlpCN	Pharmacodynamic (PD) blood samples (10 mL) for antibody concentration specific for AlpCN, RibN, Alp1N and Alp2/3N will be collected during the study	Baseline (Year 0), Years 1, 2, 3, 4
Ig G Antibody Responses Specific to Alp: RibN	Pharmacodynamic (PD) blood samples (10 mL) for antibody concentration specific for AlpCN, RibN, Alp1N and Alp2/3N will be collected during the study	Baseline (Year 0), Years 1, 2, 3, 4
Ig G Antibody Responses Specific to Alp: Alp1N	Pharmacodynamic (PD) blood samples (10 mL) for antibody concentration specific for AlpCN, RibN, Alp1N and Alp2/3N will be collected during the study	Baseline (Year 0), Years 1, 2, 3, 4
Ig G Antibody Responses Specific to Alp: Alp2-3N	Pharmacodynamic (PD) blood samples (10 mL) for antibody concentration specific for AlpCN, RibN, Alp1N and Alp2/3N will be collected during the study	Baseline (Year 0), Years 1, 2, 3, 4

Collaborators and Investigators

• Sponsor: Minervax ApS
• Collaborators: Simbec-Orion Group
• Investigators: Study Director: Ebbe Englev, Study Director

Study record dates

Study Major Dates

• Study Start (Actual): January 18, 2024
• Primary Completion (Actual): December 1, 2025
• Study Completion (Actual): December 1, 2025

Study Registration Dates

• First Submitted: February 19, 2024
• First Submitted That Met QC Criteria: February 19, 2024
• First Posted (Actual): February 28, 2024

Study Record Updates

• Last Update Posted (Actual): February 25, 2026
• Last Update Submitted That Met QC Criteria: February 23, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Streptococcal Infections
• Other Study ID Numbers: MVX0007; 332126 (Other Identifier: IRAS)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No